Multi-receptor targeted therapy of breast cancer and brain metastases with a novel QUAD-drug conjugate
QUAD-DM1 is a novel multivalent drug conjugate that appears to be highly suitable for the treatment of breast cancer and related brain metastases. The drug candidate can be administered systemically, due to its favorable toxicity profile, or loco-regionally.
Authors
- Alexandra Thomas (ORCID: https://orcid.org/0000-0003-2754-721X)
- Ralph B. D’Agostino (ORCID: https://orcid.org/0000-0002-3550-8395)
- John H. Rossmeisl (ORCID: https://orcid.org/0000-0003-1655-7076)
- Ryan T. Mott
- Waldemar Debinski
- Denise Herpai
- Kounosuke Watabe
- Kaitlin N Fink
Institutions
- Atrium Health Wake Forest Baptist (US)
- Duke Cancer Institute
- Wake Forest University (US)
- Virginia Tech (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-10-27
- DOI
- https://doi.org/10.1186/s13058-025-02100-y
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Comprehensive Cancer Center at Wake Forest Baptist Medical Center
- National Institutes of Health
- National Cancer Institute